The aim of the Partnership for Dengue Control (PDC) is to cast a wider net to facilitate and expedite urgently needed technology development, both for research and to be rolled out in countries affected by arboviral diseases.
This workshop was organized, therefore, by the PDC and the Mérieux Foundations, with the support of the Bill & Melinda Gates Foundation, bioMérieux, Takeda and Sanofi Pasteur. Its purpose was to identify the gaps in the diagnosis of these viral infections, to review the new technological innovations that may be available to fill those gaps and to promote and develop mechanisms for accelerating the pathway from tool development to impact.
Critical need
The driving force behind the event was the critical need for more sensitive, specific and accurate diagnostic tests to support more effective surveillance and prevention and to halt the increased frequency and magnitude of epidemics and the higher incidence of severe disease outcomes caused by Zika, dengue and other arboviral infections.
Workshop outcomes
Key insights emerged to the 3 questions posed during the workshop:
Where are where are we now?
Diagnostic methods to detect DENV and ZIKV infections are still mainly laboratory-based and require further clinical evaluations,
Few validated assays are available on the market to differentiate ZIKV from other flavivirus infections,
Diagnostics that can be used at or near the point-of-patient care (POC) to detect and discriminate between the different flaviviral infections are needed.
Where do we go?
Towards specific molecular, serological, antigen-based and combination assays to identify and differentiate co-circulating flaviviral infections at or near POC, as well as for surveillance, in the intermediate and long-term future.
How do we make it happen?
Identify and address challenges: uncoordinated efforts, lack of funding mechanisms, limited access to well-characterized clinical samples, lack of definition of evaluation methods and sites, lack of regulatory harmonization, market opacity, low guarantee of return on investment (ROI), as well as slow and fragmented pathway to implementation,
Offer solutions: establish early partnerships and promote information sharing, facilitate access to samples and standardized protocols, promote regulatory harmonization, define priorities and build diagnostic preparedness strategies.
Workshop Report
Approximately 80 people attended the event including participants from academia, industry, NGOs, UN agencies (including WHO), investor organizations, policy makers and regulatory bodies. A full report has been published and includes a full list of participants and a summary of all the presentations, comments and strategies that resulted from the 3-day event.
Cutting edge innovations for the intermediate and long-term future
Discussion
Near-care molecular testing for Dengue, Zika and related pathogens – Jesse Waggoner, Emory University Download Presentation
Tetracore T-COR8 diagnostic system for the detection of Dengue and other arboviruses using real-time-rtPCR at the point-of-care – Bill Nelson, Tetracore Download Presentation
Triplex PCR ZIKV/DENV/CHIKV assay and simple to operate real-time portable device – Craig Mosman, Kirkland Biosciences Download Presentation
Molecular test to detect dengue, Zika & Chikungunya and run on the QuRapID LV platform – Emily Adams, LSTM & David Edge, BioGene Download Presentation
NS1 antigen capture assays for the specific detection of different dengue virus serotypes and other arboviruses – Katharina Roeltgen, Swiss TPH Download Presentation
Multiplex Diagnosis kit for Zika, Dengue, Chikungunya and Japanese Encephalitis Viruses using Printed Array Strip based on Single-stranded Tag Hybridization method – Takahiro Haruyama, AVSS Download Presentation
Session 4: Detecting past infections Chairs: Eva Harris, Aravinda de Silva
Dx antigen discovery and imminent technological innovations
New discoveries about the molecular specificity of the human antibody response to dengue and Zika viruses – Aravinda de Silva, UNC Download Presentation
NS1 blockade-of-binding ELISA distinguishes between dengue and Zika virus antibodies – David Corti – Humabs BioMed SA Download Presentation
In-country development and evaluation of new molecular and serological methods for Zika diagnosis and surveillance and their applications – Eva Harris, Berkeley University Download Presentation
Cutting Edge Innovations For The Intermediate And Long-Term Future
VIDAS Zika and Dengue: Preliminary results on an automated immunoAssay platform – Nathalie Renard, Biomerieux Download Presentation
A nanoscale plasmonic-gold platform for specific diagnosis of Zika and differentiation from other Flavivirus infections – Benjamin A. Pinsky, Stanford, CA Download Presentation
Thursday, May 4 – Day 3
How do we make it happen? From idea to market
Session 5: Preparing for the inevitable: open technology platforms for rapid outbreak response Chairs: Bill Rodriguez, Bernadette Murgue
Preparing for the inevitable: open platform technologies for rapid outbreak response
WHO call for open technology platforms to accelerate test development – Bernadette Murgue, WHO Blueprint Download Presentation
">
The aim of the Partnership for Dengue Control (PDC) is to cast a wider net to facilitate and expedite urgently needed technology development, both for research and to be rolled out in countries affected by arboviral diseases.
This workshop was organized, therefore, by the PDC and the Mérieux Foundations, with the support of the Bill & Melinda Gates Foundation, bioMérieux, Takeda and Sanofi Pasteur. Its purpose was to identify the gaps in the diagnosis of these viral infections, to review the new technological innovations that may be available to fill those gaps and to promote and develop mechanisms for accelerating the pathway from tool development to impact.
Critical need
The driving force behind the event was the critical need for more sensitive, specific and accurate diagnostic tests to support more effective surveillance and prevention and to halt the increased frequency and magnitude of epidemics and the higher incidence of severe disease outcomes caused by Zika, dengue and other arboviral infections.
Workshop outcomes
Key insights emerged to the 3 questions posed during the workshop:
Where are where are we now?
Diagnostic methods to detect DENV and ZIKV infections are still mainly laboratory-based and require further clinical evaluations,
Few validated assays are available on the market to differentiate ZIKV from other flavivirus infections,
Diagnostics that can be used at or near the point-of-patient care (POC) to detect and discriminate between the different flaviviral infections are needed.
Where do we go?
Towards specific molecular, serological, antigen-based and combination assays to identify and differentiate co-circulating flaviviral infections at or near POC, as well as for surveillance, in the intermediate and long-term future.
How do we make it happen?
Identify and address challenges: uncoordinated efforts, lack of funding mechanisms, limited access to well-characterized clinical samples, lack of definition of evaluation methods and sites, lack of regulatory harmonization, market opacity, low guarantee of return on investment (ROI), as well as slow and fragmented pathway to implementation,
Offer solutions: establish early partnerships and promote information sharing, facilitate access to samples and standardized protocols, promote regulatory harmonization, define priorities and build diagnostic preparedness strategies.
Workshop Report
Approximately 80 people attended the event including participants from academia, industry, NGOs, UN agencies (including WHO), investor organizations, policy makers and regulatory bodies. A full report has been published and includes a full list of participants and a summary of all the presentations, comments and strategies that resulted from the 3-day event.
Cutting edge innovations for the intermediate and long-term future
Discussion
Near-care molecular testing for Dengue, Zika and related pathogens – Jesse Waggoner, Emory University Download Presentation
Tetracore T-COR8 diagnostic system for the detection of Dengue and other arboviruses using real-time-rtPCR at the point-of-care – Bill Nelson, Tetracore Download Presentation
Triplex PCR ZIKV/DENV/CHIKV assay and simple to operate real-time portable device – Craig Mosman, Kirkland Biosciences Download Presentation
Molecular test to detect dengue, Zika & Chikungunya and run on the QuRapID LV platform – Emily Adams, LSTM & David Edge, BioGene Download Presentation
NS1 antigen capture assays for the specific detection of different dengue virus serotypes and other arboviruses – Katharina Roeltgen, Swiss TPH Download Presentation
Multiplex Diagnosis kit for Zika, Dengue, Chikungunya and Japanese Encephalitis Viruses using Printed Array Strip based on Single-stranded Tag Hybridization method – Takahiro Haruyama, AVSS Download Presentation
Session 4: Detecting past infections Chairs: Eva Harris, Aravinda de Silva
Dx antigen discovery and imminent technological innovations
New discoveries about the molecular specificity of the human antibody response to dengue and Zika viruses – Aravinda de Silva, UNC Download Presentation
NS1 blockade-of-binding ELISA distinguishes between dengue and Zika virus antibodies – David Corti – Humabs BioMed SA Download Presentation
In-country development and evaluation of new molecular and serological methods for Zika diagnosis and surveillance and their applications – Eva Harris, Berkeley University Download Presentation
Cutting Edge Innovations For The Intermediate And Long-Term Future
VIDAS Zika and Dengue: Preliminary results on an automated immunoAssay platform – Nathalie Renard, Biomerieux Download Presentation
A nanoscale plasmonic-gold platform for specific diagnosis of Zika and differentiation from other Flavivirus infections – Benjamin A. Pinsky, Stanford, CA Download Presentation
Thursday, May 4 – Day 3
How do we make it happen? From idea to market
Session 5: Preparing for the inevitable: open technology platforms for rapid outbreak response Chairs: Bill Rodriguez, Bernadette Murgue
Preparing for the inevitable: open platform technologies for rapid outbreak response
WHO call for open technology platforms to accelerate test development – Bernadette Murgue, WHO Blueprint Download Presentation
" />
New and Innovative Approaches to Laboratory Diagnosis of Zika, Dengue and other Arboviruses - Global Dengue & Aedes-Transmitted Diseases Consortium (GDAC)
May 2-4, 2017 - Les Pensières Center for Global Health, Veyrier du Lac, France
The aim of the Partnership for Dengue Control (PDC) is to cast a wider net to facilitate and expedite urgently needed technology development, both for research and to be rolled out in countries affected by arboviral diseases.
This workshop was organized, therefore, by the PDC and the Mérieux Foundations, with the support of the Bill & Melinda Gates Foundation, bioMérieux, Takeda and Sanofi Pasteur. Its purpose was to identify the gaps in the diagnosis of these viral infections, to review the new technological innovations that may be available to fill those gaps and to promote and develop mechanisms for accelerating the pathway from tool development to impact.
Critical need
The driving force behind the event was the critical need for more sensitive, specific and accurate diagnostic tests to support more effective surveillance and prevention and to halt the increased frequency and magnitude of epidemics and the higher incidence of severe disease outcomes caused by Zika, dengue and other arboviral infections.
Workshop outcomes
Key insights emerged to the 3 questions posed during the workshop:
Where are where are we now?
Diagnostic methods to detect DENV and ZIKV infections are still mainly laboratory-based and require further clinical evaluations,
Few validated assays are available on the market to differentiate ZIKV from other flavivirus infections,
Diagnostics that can be used at or near the point-of-patient care (POC) to detect and discriminate between the different flaviviral infections are needed.
Where do we go?
Towards specific molecular, serological, antigen-based and combination assays to identify and differentiate co-circulating flaviviral infections at or near POC, as well as for surveillance, in the intermediate and long-term future.
How do we make it happen?
Identify and address challenges: uncoordinated efforts, lack of funding mechanisms, limited access to well-characterized clinical samples, lack of definition of evaluation methods and sites, lack of regulatory harmonization, market opacity, low guarantee of return on investment (ROI), as well as slow and fragmented pathway to implementation,
Offer solutions: establish early partnerships and promote information sharing, facilitate access to samples and standardized protocols, promote regulatory harmonization, define priorities and build diagnostic preparedness strategies.
Workshop Report
Approximately 80 people attended the event including participants from academia, industry, NGOs, UN agencies (including WHO), investor organizations, policy makers and regulatory bodies. A full report has been published and includes a full list of participants and a summary of all the presentations, comments and strategies that resulted from the 3-day event.
Cutting edge innovations for the intermediate and long-term future
Discussion
Near-care molecular testing for Dengue, Zika and related pathogens – Jesse Waggoner, Emory University Download Presentation
Tetracore T-COR8 diagnostic system for the detection of Dengue and other arboviruses using real-time-rtPCR at the point-of-care – Bill Nelson, Tetracore Download Presentation
Triplex PCR ZIKV/DENV/CHIKV assay and simple to operate real-time portable device – Craig Mosman, Kirkland Biosciences Download Presentation
Molecular test to detect dengue, Zika & Chikungunya and run on the QuRapID LV platform – Emily Adams, LSTM & David Edge, BioGene Download Presentation
NS1 antigen capture assays for the specific detection of different dengue virus serotypes and other arboviruses – Katharina Roeltgen, Swiss TPH Download Presentation
Multiplex Diagnosis kit for Zika, Dengue, Chikungunya and Japanese Encephalitis Viruses using Printed Array Strip based on Single-stranded Tag Hybridization method – Takahiro Haruyama, AVSS Download Presentation
Session 4: Detecting past infections Chairs: Eva Harris, Aravinda de Silva
Dx antigen discovery and imminent technological innovations
New discoveries about the molecular specificity of the human antibody response to dengue and Zika viruses – Aravinda de Silva, UNC Download Presentation
NS1 blockade-of-binding ELISA distinguishes between dengue and Zika virus antibodies – David Corti – Humabs BioMed SA Download Presentation
In-country development and evaluation of new molecular and serological methods for Zika diagnosis and surveillance and their applications – Eva Harris, Berkeley University Download Presentation
Cutting Edge Innovations For The Intermediate And Long-Term Future
VIDAS Zika and Dengue: Preliminary results on an automated immunoAssay platform – Nathalie Renard, Biomerieux Download Presentation
A nanoscale plasmonic-gold platform for specific diagnosis of Zika and differentiation from other Flavivirus infections – Benjamin A. Pinsky, Stanford, CA Download Presentation
Thursday, May 4 – Day 3
How do we make it happen? From idea to market
Session 5: Preparing for the inevitable: open technology platforms for rapid outbreak response Chairs: Bill Rodriguez, Bernadette Murgue
Preparing for the inevitable: open platform technologies for rapid outbreak response
WHO call for open technology platforms to accelerate test development – Bernadette Murgue, WHO Blueprint Download Presentation
We use cookies to ensure you have the best experience on our website. If you continue to use them, we will consider that you accept the use of cookies.Ok
